Pharma Stocks Rise: U.S. Tariff Relief, Strong Domestic Growth Drive Sector Outlook

Pharma stocks are gaining attention after the U.S. clarified tariff exemptions for India and other countries on certain specialty chemicals. G Chokkalingam, Founder & MD, Equinomics Research, explains why the development has eased a key concern for investors. He also highlights the domestic pharma industry’s 9–10% growth, improving export realisations and the benefit of rupee depreciation for pharmaceutical companies. Unlike IT, where currency weakness has offered limited support, pharma exporters may be better positioned to benefit from improved realisations. The discussion also explores why the sector could remain robust amid ongoing global trade uncertainties and market volatility.